The European Union cannot reach consensus on what to do with the AstraZeneca vaccine Coronavirus

PÚBLICO is not compatible with Internet Explorer 10 or lower. Please update your browser.

While several countries decided to suspend administration of the AstraZeneca vaccine below a certain age, and if there is two days to the largest mass vaccination of this drug in Portugal (200,000 teachers and non-teachers), national health authorities have not clarified what they are up to after the European Medicines Agency (EMA) concluded that cases of thrombosis with a marked decrease in the number of platelets in the blood in people who have taken this medicine should be considered a rare side effect of this vaccine. Still, the EMA emphasized that the benefits of using outweigh the risks.


Print output

April 8, 2021

See more


Receive notifications when we publish text by this author or on the topics of this article.

These are the authors and subjects that you have chosen to follow. You can turn notifications on or off.


Back to top button